Objective: To study the feasibility and efficacy of percutaneous interventional occlusion in patients with perimembranous ventricular septal defect combined with severe tricuspid regurgitation. METHODS: Twenty-seven patients with perimembranous ventricular septal defect combined with severe tricuspid regurgitation were selected, and the cause of tricuspid regurgitation was “left-to-right transventricular septal blood flow directly impacting the tricuspid valve leaflets or their tendons”. The degree of postoperative tricuspid regurgitation, surgical success rate, complication rate, and postoperative hospital stay, total cost, and operative time were compared between the two groups at 6-12 months of follow-up. Results: The technical success rate was 100% in both groups. The postoperative tricuspid regurgitation was significantly reduced in both groups compared with the preoperative period, and there was no tricuspid regurgitation of more than mild degree. The interventional group had a complication rate of 20%, an operative time of 30.15±16.04 min, a postoperative ICU time of 0 days, and a hospitalization cost of $30,200±0.12 million. The surgical group had a complication rate of 25%, an operation time of 79.68±21.48 min, a postoperative ICU time of 1.61±0.63 days, and an inpatient cost of $25,100±0.16 million. There were no fatal cases in both groups at 5 to 12 months of follow-up. CONCLUSIONS: Preoperatively, after strict ultrasound screening, percutaneous interventional occlusion therapy is a safe and effective treatment for patients with perimembranous ventricular septal defect combined with severe tricuspid valve pseudoreflux.